Losartil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losartil

Property Description
Active ingredient Losartan potassium
Form Oral, film-coated tablet (single-entity product)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Antihypertensive agent (reduces blood pressure)
Origin Synthetic, non-peptide compound

What is Losartil and What is its Active Ingredient?

Losartil is a widely recognized prescription-only medicine whose identity is established by its active substance, Losartan potassium. The compound is a synthetic, non-peptide molecule created for oral use and is typically supplied as an oral, film-coated tablet. As a single-entity product, Losartil's therapeutic actions are derived exclusively from Losartan, distinguishing it from formulations that combine multiple active ingredients.

To Which Class of Medicines Does Losartil Belong?

Losartil is classified pharmacologically as an Angiotensin II Receptor Blocker (ARB), which is an mathrmAT1 receptor antagonist. This class of medication is essential for managing the Renin-Angiotensin-Aldosterone System (RAAS). The ARB classification differentiates Losartil from other antihypertensive categories, such as older Angiotensin-Converting Enzyme (ACE) inhibitors, by intervening at a distinct point in the signaling pathway.

What is the General Purpose of Losartil?

The overall purpose of Losartil is to function as an effective antihypertensive agent, with the general therapeutic goal of achieving and sustaining the reduction of elevated blood pressure. This is accomplished by interfering with the body's natural signaling system that promotes the constriction of blood vessels. By facilitating the widening of these vessels, Losartil contributes to lowering the resistance against which the heart pumps blood, thereby reducing mechanical strain and stabilizing overall circulatory control.

What side effects are possible with Losartil?

Possible Side Effects and Safety Information

The safety profile of Losartil (Losartan) is formally documented in government regulatory labeling, categorizing possible adverse reactions by frequency and physiological system. This information is non-advisory and focuses strictly on officially listed effects.

Frequency-Classified Adverse Reactions

The most frequently reported effects are classified as Common (occurring in 1 in 10 to 1 in 100 individuals) and may include dizziness, headache, fatigue, and upper respiratory infection. Reactions classified as Uncommon (occurring in 1 in 100 to 1 in 1,000) include symptomatic hypotension, rash, and gastrointestinal effects like constipation or vomiting. Low-incidence reactions are classified as Rare, such as anaphylactic reactions and angioedema (swelling of the face, throat, and tongue).

System-Organ Classes and Serious Reactions

Adverse events are grouped by the physiological system affected, including the Nervous System, Vascular System, and Metabolism and Nutrition Disorders (e.g., hyperkalemia). The regulatory safety profile highlights serious potential reactions, including the rare possibility of Angioedema and potential for severe Hepatic Dysfunction.

Population-Specific Safety Constraints

Official labeling includes critical restrictions for specific patient groups. Losartil is Contraindicated during the second and third trimesters of pregnancy due to the severe risk of fetal injury. For patients with hepatic impairment, a lower starting dose is required. Furthermore, safety documentation notes that effects like hypotension may be more likely at the initiation of treatment or in volume-depleted patients.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section reflects the officially documented descriptions of overdose and mandated emergency actions as stated in government regulatory sources for Losartan potassium.

Documented Clinical Manifestations

Regulatory documents state that an overdose of Losartil is most likely to result in hypotension (abnormally low blood pressure), which is the primary documented clinical manifestation. This may be accompanied by alterations in heart rhythm, specifically tachycardia (increased heart rate) or, conversely, bradycardia (decreased heart rate), which may occur due to changes in vagal stimulation.

Required Emergency Actions

Due to the risk of severe hypotension, regulatory authorities explicitly mandate that users seek immediate emergency medical attention upon suspicion of an overdose. The management of overdose is symptomatic and supportive; for instance, the administration of intravenous normal saline is described for restoring blood volume in cases of symptomatic hypotension. The regulatory labels state that no specific antidote is known for Losartil, and the active compound is not expected to be removed by hemodialysis.

Population-Specific Risk

Official prescribing information notes a severe population-specific risk related to exposure during the second and third trimesters of pregnancy, which may lead to serious complications for the fetus, including renal failure and death.

Therapeutic Uses of Losartil

What Losartil Treats: Main Uses and Benefits

Losartil (Losartan) may be part of symptomatic management for several chronic cardiovascular and renal conditions, with the relevant goal of supporting risk mitigation. The medication is commonly used to help manage conditions like essential hypertension, diabetic nephropathy in Type 2 Diabetes, Left Ventricular Hypertrophy (LVH), and chronic heart failure. This therapeutic focus is on systemic conditions where long-term management may assist with maintaining functional stability.

The medication may assist with easing the overall symptom load by achieving sustained blood pressure reduction and providing organ-specific support. It is commonly used to help with lowering the risk of cardiovascular events, such as stroke, and to slow the progression of kidney damage evidenced by addressing proteinuria.

“The relevant goal is to help patients cope more steadily with chronic disease, supporting the mitigation of long-term risk.”


Quick Fact: Relief for Chronic Systemic Pressure Losartil helps address symptoms related to heightened physiological activity, contributing to support general well-being and managing cardiovascular burden.

Regulatory References

  1. DailyMed (NIH/NLM) Label Information for Losartan Potassium

Eligibility and Restrictions for Use

Losartil's official regulatory profile defines patient eligibility based on age, physiological status, and concurrent conditions, as mandated by government authorities.

Populations Excluded from Use (Contraindications)

Use of Losartil is formally prohibited for patients with known hypersensitivity to Losartan or its components. It is strictly contraindicated after the first three months of pregnancy (the second and third trimesters). Use is also prohibited in patients with severely reduced liver function (severe hepatic impairment). Furthermore, co-administration with aliskiren is contraindicated in patients with Type 2 diabetes or moderate-to-severe kidney impairment.

Age and Conditional Restrictions

Losartil is generally approved for adults and adolescents aged 6 years and older for hypertension. Use is not recommended for children under 6 years old, as safety and efficacy have not been established in this group. For patients with mild-to-moderate liver impairment or those with intravascular volume depletion, regulators advise special consideration and a lower starting dose. Use is not recommended for breastfeeding mothers or during the first trimester of pregnancy. Regulatory documents also note specific limitations, such as the stroke reduction benefit not applying to Black patients with Left Ventricular Hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Losartil's official interaction profile involves medicinal product categories that affect the Renin-Angiotensin-Aldosterone System (RAAS), modulate serum potassium levels, and alter cytochrome P450 (CYP) enzymes. Explicitly listed interacting substances include Aliskiren, ACE Inhibitors, Lithium, Fluconazole, Rifampin, and Potassium-sparing diuretics.

Interaction-Related Constraints

A formal co-administration prohibition is documented for Aliskiren in patients with diabetes mellitus due to the associated risk of severe adverse outcomes. The regulatory profile notes that mild-to-moderate hepatic impairment is a population-specific factor resulting in significantly increased Losartil plasma concentrations, requiring specific consideration. No mandatory timing separation rules are documented for the Losartil single-entity product.

Documented Interaction Statements

  • Pharmacodynamic Interactions: Combining with Potassium-sparing diuretics or Potassium-containing salt substitutes carries a documented risk of hyperkalemia. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to diminish the antihypertensive effect and increase the risk of renal function impairment.
  • Pharmacokinetic Interactions: The CYP2C9 inhibitor Fluconazole and the inducer Rifampin both are documented to reduce the plasma exposure of the active metabolite.

The overall regulatory structure defines Losartil's interaction profile through documented pharmacodynamic reinforcement—particularly concerning RAAS blockade and potassium balance—and pharmacokinetic modulation involving the CYP2C9/3A4 metabolic pathways. This necessitates specific regulatory constraints for clinically significant exposure alterations and additive effects on blood pressure.

Mechanism of Action

Losartil is an Angiotensin II Receptor Blocker (ARB) that modulates the Renin-Angiotensin-Aldosterone System (RAAS).

Losartil functions primarily as a competitive antagonist at the Angiotensin II Type 1 receptor (AT1 receptor), which is expressed in vascular smooth muscle, adrenal glands, and kidneys. It binds selectively to the AT1 receptor, thereby preventing the endogenous hormone Angiotensin II from docking and initiating its typical signaling cascade.

This inhibition of AT1 receptor activity prevents two key downstream effects: the AT1-mediated signaling for vasoconstriction in arterial smooth muscle and the stimulation of aldosterone release from the adrenal cortex. The molecular consequence is a suppression of cell contraction and volume regulation signals.

At the system level, this pathway modulation results in arterial vasodilation and a reduction in fluid retention. The physiological consequence is a decrease in overall systemic vascular resistance and a reduction of the afterload imposed on the cardiac system.

Dosage and Administration Information

Administration Scope

Entity Instruction (Strictly Label-Based)
Route of administration Oral use only as a film-coated tablet.
Dosing schedule (Adults) Starting Dose (General): Typically 50 mg once daily. Starting Dose (Sensitive Populations): 25 mg once daily is recommended for volume-depleted patients or those with hepatic impairment. Maximum Daily Dose: 100 mg.
Frequency and Timing Primarily taken once daily (QD). The total daily dose may be divided and administered as two doses per day (BID) if necessary to maintain control.
Timing in relation to meals May be administered with or without food.
Preparation requirements The tablet must be swallowed whole with a glass of water. No dilution or reconstitution is required for the tablet form.
Age-group administration rules Older Adults (ge 65 years): No initial dose adjustment is generally necessary, although a lower starting dose (25 mg) may be considered in patients over 75 years of age. Pediatric Use (6-16 years): The starting dose is weight-based (0.7 mg/kg) up to a maximum of 50 mg daily.
Missed-dose rules A missed dose should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Instruction Classifications

Classification Description (Strictly Label-Based)
Administration method type Oral (tablet).
Frequency pattern Daily (once daily, potentially divided).
Regulatory basis Dosing and administration details are established by professional medical standards and standard product labeling.
Use-context constraints Intended for chronic management, with dose adjustments (titration) allowed within the 25 mg to 100 mg range based on measured response over several weeks.

The official instructions define a structured protocol for Losartil use, detailing the required oral route, the fixed dose forms, and a titratable daily range that must not exceed 100 mg. This framework establishes the necessary constraints for administration, including the primary once-daily frequency and the flexibility of taking the dose independent of meals, guiding its long-term use.

Recent Clinical Evidence

Losartil: Overview of Clinical Studies

The understanding of Losartil (Losartan) is derived from large-scale randomized controlled trials (RCTs) that evaluated its use across its main indications: high blood pressure, kidney disease in Type 2 Diabetes, and chronic heart failure. This summary describes the structure of the research and the outcomes that were monitored, avoiding any clinical advice or interpretation.


Evidence for Use in High Blood Pressure

Losartil was studied for research examining high blood pressure in populations where studies explored other related physiological factors, such as Left Ventricular Hypertrophy (LVH). These long-term RCTs, tracking patients for nearly five years, monitored a composite outcome related to major cardiovascular events (stroke, heart attack, and cardiovascular death).

Trials reported that the Losartil regimen was associated with a different pattern of these composite events when compared to a regimen based on other classes of blood pressure medicine. The data show patterns related to variations in stroke event rates observed in the studied groups. The results apply only to the populations studied, and data for low-risk hypertensive patients remain insufficient. Additionally, research explored whether the Losartil regimen was associated with changes in the heart's structure, monitoring changes in heart wall thickness (LVMI).


Evidence for Organ Protection and Heart Failure

Losartil was evaluated in research exploring conditions marked by functional limitations, specifically kidney disease (diabetic nephropathy) in patients with Type 2 Diabetes and high protein in the urine. Studies reported patterns where the measured rate of a composite renal endpoint (ESRD, doubling of serum creatinine, or death) varied between the Losartil group and the placebo group. The research did not indicate a variation in all-cause mortality between these groups.

For chronic heart failure, research was limited to patients documented as intolerant to ACE inhibitors. Trials monitored composite outcomes of death or hospitalization for heart failure, reporting that data showed patterns related to variations in the rate of hospitalization for heart failure between high-dose and low-dose regimens.

Key Studies & References

  1. Label: LOSARTAN POTASSIUM tablet, film coated - DailyMed (Official Indications and Study Summaries)
  2. Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL Study) main results
  3. Losartan - StatPearls (High-Authority Medical Review)

Frequently Asked Questions (FAQ)

Common questions about Losartil (FAQ)


Q: Why is Losartil prescribed so often?

A: Losartil is recognized by regulatory bodies for its use in several key conditions. Official product labeling identifies approved uses for managing high blood pressure, reducing stroke risk in specific patient populations, and treating kidney disease associated with Type 2 diabetes. Furthermore, the medicine is a recognized alternative for patients with heart failure who have demonstrated an intolerance to ACE inhibitors.

Q: What is the difference between Losartil and another similar drug like Lisinopril?

A: Losartil is officially classified as an Angiotensin II Receptor Blocker (ARB), which works by blocking the AT1 receptor. Regulatory information notes that this mechanism differs from the ACE inhibitor class of medicines, such as Lisinopril. Both classes address the body's system that regulates blood pressure but intervene at distinct points in the signaling pathway.

Q: Is Losartil known to cause any long-term side effects?

A: The safety data for Losartil includes information gathered from clinical trials that have tracked patients for periods lasting several years. Regulatory documents classify all documented adverse effects based on their frequency (Common, Uncommon, Rare) and do not explicitly categorize effects based on whether they are considered 'long-term' versus acute or transient.

Q: Can Losartil interact with medications for diabetes?

A: A specific safety constraint is documented regarding diabetes treatment. The co-administration of Losartil with aliskiren is strictly contraindicated (prohibited) in patients with Type 2 diabetes due to the documented potential for severe adverse outcomes. Interactions with other specific diabetes medications are generally not detailed in the official interaction statements.

Q: Is it normal to feel a bit lightheaded when starting Losartil?

A: Dizziness is listed as a Common adverse reaction in the official safety information. Regulatory documents also note the potential for effects related to low blood pressure, such as hypotension (a sudden drop in blood pressure), which may be more likely to occur when initiating treatment.

Q: Can Losartil be taken with other heart medications?

A: The official interaction profile lists specific cardiovascular-related substances, such as ACE inhibitors and potassium-sparing diuretics. Given the potential for additive effects on blood pressure, official guidance mandates specific review when considering concurrent use with other heart or blood pressure medicines.

Q: Is Losartil generic or a brand name?

A: The active substance in this prescription medicine is Losartan potassium, which is the established generic name. The product name Losartil is recognized as a brand name for the Losartan compound.

Q: How long does Losartil take to start working to lower blood pressure?

A: According to official prescribing information, the medicine starts to reduce blood pressure over time. The maximal blood pressure response may be observed within three to six weeks of consistent daily treatment, although some initial effects may be seen earlier.

Q: How long do the effects of one Losartil pill last?

A: Losartil is generally prescribed to be taken once daily. This dosing frequency is used because the medicine provides blood pressure control that lasts over a full 24-hour period.

Q: Should Losartil be taken in the morning or at night?

A: Regulatory instructions state that Losartil is typically taken once daily, with or without food. While the specific time of day is not mandated, official product information recommends maintaining a consistent schedule by taking the medicine at the same time each day.

Q: Can I stop taking Losartil if my blood pressure improves?

A: Official documentation states that Losartil is intended for the chronic management of conditions like high blood pressure. The medication is designed for long-term use.

Q: Are there any dietary supplements or vitamins that interact with Losartil?

A: The official interaction profile highlights the documented risk of high potassium (hyperkalemia) when used alongside potassium-containing salt substitutes or potassium supplements. Interactions with other common vitamins and supplements are not explicitly detailed in the specific regulatory interaction section.

Q: Is it safe to drink alcohol while taking Losartil?

A: Regulatory documents indicate that consuming alcohol may cause an additive effect with Losartil. This potential interaction could increase the risk of adverse effects like dizziness or lightheadedness due to effects on blood pressure.

Q: Is there a risk of a cough with Losartil, like with other blood pressure drugs?

A: Cough is not listed as a common, uncommon, or rare adverse reaction in the official regulatory documentation for Losartil.

Q: How does Losartil affect the body compared to diuretics?

A: Losartil acts by blocking the Angiotensin II receptor to reduce blood vessel tightening (vasoconstriction) and certain volume-regulating hormones. Diuretics, in contrast, function primarily by increasing the excretion of water and salt through the kidneys, which helps reduce fluid volume in the body.

Q: Are there any reported interactions between Losartil and cold medicines?

A: Cold medicines are a broad category, but official warnings caution that some non-prescription products, particularly those containing decongestants, may have the potential to increase blood pressure. This potential effect could interfere with the desired action of Losartil.

Q: What fruits or juices should be avoided while on Losartil?

A: Official prescribing information indicates that Losartil may be taken with or without food. No specific fruits or juices are officially mandated to be avoided in relation to taking this medicine.

Q: What kind of monitoring is typically required while taking Losartil?

A: Regulatory documents indicate the need for monitoring specific parameters related to kidney function and serum potassium levels. This monitoring is typically performed through laboratory testing, particularly during the initiation of treatment and when dosages are adjusted.

Q: Is Losartil used to treat migraines?

A: Regulatory documents define the approved uses of Losartil, which include high blood pressure and certain kidney and heart conditions. Treatment for migraines is not listed among the established, approved indications.

Q: Can Losartil affect liver function tests?

A: Official safety information notes the rare potential for severe hepatic dysfunction (severe liver problems) and requires dose consideration for patients with pre-existing liver impairment. Because of this documented risk, monitoring liver-related parameters may be included in the patient's care plan.

How should Losartil be stored and disposed of?

How to Store and Dispose of Losartan Potassium Tablets

Losartan potassium tablets must be stored at controlled room temperature, which is between 15 C to 30 C (59 F to 86 F). The medication requires protection from both light and moisture and must be kept in the original container, tightly closed, to maintain stability. A critical safety requirement is to keep the product out of the sight and reach of children.


For disposal, official instructions prohibit discarding expired or unused tablets via wastewater or household trash. Patients are directed to consult a pharmacist or utilize an official drug take-back program where available, ensuring proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Losartil found in:

A-Z Index: